Clinical trials
Relapsed/Refractory clinical trials
Below are recruiting relapsed/refractory clinical trials, each written for real people, not researchers. We’re tracking 411 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06980597RecruitingPhase 1
Testing OL-108 for active autoimmune diseases
This trial tests an investigational drug called OL-108 for people with certain autoimmune diseases (lupus, myositis, scleroderma, or vasculitis) that have come back or not responded to standard treatments. The goal is to see if it's safe and if it can help control the disease.
BeijingAges 18–65 - NCT07067346RecruitingEarly Phase 1
IR-101 for relapsed or refractory neuroblastoma
This early-phase trial tests a new drug called IR-101 for children with high-risk neuroblastoma that has come back or isn't responding to treatment. It aims to see if the drug is safe and can help shrink tumors that show up on a MIBG scan.
Chengdu, SichuangAges 1 year+ - NCT07062627RecruitingPhase 2
CAR-T cell therapy for CNS lymphoma
This trial tests a new treatment called Anbalcabtagene Autoleucel (a type of CAR-T cell therapy) for people whose B-cell lymphoma has come back or not responded to treatment, specifically when it affects the brain or spinal cord. The goal is to see if this therapy can help control the disease.
SeoulAges 19 years+ - NCT07053670RecruitingPhase 1
Study of CT1190B for relapsed or refractory B-cell lymphoma
This study tests a new cancer treatment called CT1190B for people with certain types of B-cell lymphoma that have not responded to or came back after other treatments. The goal is to see if it can help shrink or control the lymphoma.
Wuhang, HubeiAges 18–75 - NCT07052305RecruitingPhase 1
Testing NT-I7 after CAR T-cell therapy for large B-cell lymphoma
This trial tests whether a drug called NT-I7 (efineptakin alfa) can help people with large B-cell lymphoma who have already received a CAR T-cell treatment like Yescarta or Breyanzi. It aims to boost your immune system's recovery and improve outcomes.
St Louis, MissouriAges 18 years+ - NCT07044050RecruitingPhase 1
Study of OT-C001 natural killer cells for large B cell lymphoma
This trial tests a new treatment made from specially activated natural killer cells from a donor. It is for people with diffuse large B cell lymphoma that has come back or not responded to other treatments, including CAR T-cell therapy.
MontpellierAges 18 years+ - NCT07021989RecruitingPhase 2
ctDNA-Guided Therapy for Relapsed Hodgkin Lymphoma
This trial uses a blood test (ctDNA) to guide treatment for Hodgkin lymphoma that has come back or not responded to one prior treatment. You would receive a combination of drugs (pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin) to see if it works better.
Davis, CaliforniaAges 18 years+ - NCT06797024Recruiting
Study of JY231 injection for tough nerve immune disorders
This trial tests a new injection called JY231 for people with certain hard-to-treat nerve and immune disorders that haven't improved with standard treatments. It aims to see if this experimental therapy can help control the disease when other options have failed.
Wuhan, HubeiAges 18–75 - NCT07013565RecruitingPhase 2
Chemoimmunotherapy for ALK+ ALCL that has come back
This trial tests a combination of chemotherapy and immunotherapy for children and adults with a type of lymphoma called ALK-positive anaplastic large cell lymphoma that has returned or not responded to previous treatment. The goal is to see if this new approach can help control the disease.
Valhalla, New YorkAges 1–39 - NCT06995872RecruitingPhase 1
Study of rhIL-15 with immunotherapy and chemo for neuroblastoma
This trial tests a new combination of drugs (rhIL-15, dinutuximab, irinotecan, and temozolomide) for children and young adults whose neuroblastoma has come back or hasn't responded to other treatments. The goal is to see if this mix can help shrink or control the cancer.
Bethesda, MarylandAges 3–35 - NCT07001540RecruitingPhase 2
Targeted drug combo for relapsed DLBCL
This trial tests a combination of targeted antibody drugs (polatuzumab vedotin and rituximab) plus two chemo drugs (gemcitabine and oxaliplatin) for people with DLBCL whose cancer returned after their first treatment and who cannot have a stem cell transplant. The goal is to see if this combination works better as a second-line treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06414148RecruitingPhase 2
Epcoritamab with or without lenalidomide and rituximab after CAR T
This trial tests whether adding a drug called epcoritamab (with or without two other drugs, lenalidomide and rituximab) can help people with large B-cell lymphoma whose cancer was still detectable after CAR T-cell therapy. It aims to stop the cancer from coming back.
Camperdown, New South WalesAges 16 years+ - NCT06973356Recruiting
CAR-T therapy for severe, hard-to-treat ITP
This trial tests a new type of immunotherapy called CAR-T cells that target two proteins (CD19 and BCMA) on immune cells. It is for adults with severe ITP that has not improved with other treatments. The goal is to reset the immune system to stop attacking platelets.
Changsha, HunanAges 18 years+ - NCT06973187RecruitingPhase 3
Comparing two drugs for CLL or SLL after prior treatment
This trial tests a new drug (BGB-16673) against another drug (pirtobrutinib) for people with CLL or SLL that hasn't responded to or has come back after a prior BTK inhibitor treatment. The goal is to see which drug is more effective and safe.
Birmingham, AlabamaAges 18 years+ - NCT06940960Recruiting
JY231 cell therapy for relapsed B-cell lymphoma or leukemia
This trial tests a new cell therapy (JY231) for people whose B-cell lymphoma or leukemia (B-ALL) has returned or not responded to earlier treatments. The therapy uses your own T cells, modified to target the CD19 marker on cancer cells.
Guangzhou, GuangdongAges 12–75 - NCT06948786RecruitingPhase 2
Pirtobrutinib and Mosunetuzumab for relapsed follicular lymphoma
This trial tests two new drugs, pirtobrutinib and mosunetuzumab, for people with follicular lymphoma that has come back or not responded to earlier treatments. The goal is to see if this combination can help control the cancer.
Seattle, WashingtonAges 18 years+ - NCT06934382RecruitingPhase 1
CAR-T cell therapy for relapsed T-cell leukemia or lymphoma
This trial tests a new type of immunotherapy called anti-CD7 CAR-T cells for children and young adults with T-cell acute lymphoblastic leukemia or lymphoma that has come back or not responded to standard treatments. The goal is to see if these specially engineered immune cells can find and destroy cancer cells that carry the CD7 protein.
Philadelphia, PennsylvaniaAges birth–29 years - NCT06936748RecruitingPhase 2
Radiation plus immunotherapy for large relapsed solid tumors
This trial tests a new combination of radiation therapy and two immunotherapy drugs (Iparomlimab and Tuvonralimab) for people whose solid tumors have returned or spread and are too large for standard surgery. The goal is to shrink the tumor and control the cancer.
Nanchang, JiangxiAges 18–75 - NCT06930651RecruitingPhase 1/Phase 2
Engineered NK cell therapy for relapsed blood cancers
This trial tests a new immune cell therapy (engineered NK cells) for people with certain blood cancers like AML, MDS, or CMML that have not responded to standard treatments. The therapy aims to help your immune system attack cancer cells, and is given after a short course of chemotherapy.
Houston, TexasAges 18–80 - NCT06911502RecruitingPhase 3
Golcadomide plus rituximab for relapsed follicular lymphoma
This trial tests a new drug, Golcadomide, combined with rituximab, for people with follicular lymphoma that has come back or hasn't responded to prior treatment. The goal is to see if this combination works better than other treatments your doctor might choose.
Birmingham, AlabamaAges 18 years+ - NCT06892678RecruitingPhase 1/Phase 2
DFMO maintenance for relapsed Ewing sarcoma or osteosarcoma
This trial tests a drug called DFMO given as maintenance therapy to keep cancer from coming back. It is for people under 40 who have finished treatment for relapsed Ewing sarcoma or osteosarcoma and currently show no signs of cancer.
The Bronx, New YorkAges Up to 39 years - NCT06890494RecruitingEarly Phase 1
BiTE-EV for relapsed or hard-to-treat B-cell leukemia
This trial tests a new immunotherapy drug called BiTE-EV for people with B-cell acute lymphoblastic leukemia that has come back after treatment or is not responding well. The drug is designed to help your immune system find and kill cancer cells.
BeijingAges 18–70 - NCT06874946RecruitingPhase 1/Phase 2
Nanobody-based CAR-T cells for relapsed T-cell leukemia or lymphoma
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are reprogrammed to find and destroy T-cell leukemia or lymphoma cells that have the CD5 protein. It may be an option if your cancer has come back or hasn't responded to other treatments.
Beijing, Beijing MunicipalityAges 3–70 - NCT06873659RecruitingPhase 1
Testing SON-DP for advanced solid tumors
This trial tests a new drug called SON-DP for people with advanced solid tumors that haven't responded to standard treatments. It aims to see if the drug is safe and helps shrink or control the cancer.
Beijing, Beijing MunicipalityAges 18–75
Hear when a new Relapsed/Refractory trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed/refractory?
- Yes. Clin2 currently lists 411 recruiting relapsed/refractory studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed/refractory trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed/refractory trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory Multiple Myeloma
- Relapsed/Refractory Acute Myeloid Leukemia
- Relapsed or Refractory Multiple Myeloma
- Relapsed or Refractory Multiple Myeloma (RRMM)
- Relapsed/Refractory B-cell Lymphoma
- Relapsed/Refractory B-cell Malignancies
- Non-Hodgkin Lymphoma Refractory/ Relapsed
- Relapsed or Refractory Acute Myeloid Leukemia (AML)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.